Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program

被引：0
|
作者：
Xin Du
Jie Jin
Zhen Cai
Fangping Chen
Dao-bin Zhou
Li Yu
Xiaoyan Ke
Xiao Li
Depei Wu
Fanyi Meng
Dena DeMarco
Jingshan Zhang
Jay Mei
Jian Hou
机构：
[1] Guangdong General Hospital,The 1st Affiliated Hospital
[2] Zhejiang University,Department of Hematology
[3] Xiangya Hospital of Central South University,undefined
[4] Peking Union Medical College Hospital,undefined
[5] The 301 Hospital-Chinese PLA General Hospital,undefined
[6] Peking University Third Hospital,undefined
[7] Shanghai 6th Hospital,undefined
[8] The 1st Affiliated Hospital of Soochow University,undefined
[9] Nanfang Hospital of Southern Medicine University in Guangzhou,undefined
[10] Celgene Corporation,undefined
[11] Shanghai Changzheng Hospital,undefined
来源：
BMC Cancer | / 16卷
关键词：
Relapsed/refractory multiple myeloma; Chinese patients; Lenalidomide; Low-dose dexamethasone; Dexamethasone;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma
    Zagouri, Flora
    Roussou, Maria
    Kastritis, Efstathios
    Gavriatopoulou, Maria
    Eleutherakis-Papaiakovou, Evangelos
    Kanellias, Nikolaos
    Kalapanida, Despoina
    Christoulas, Dimitrios
    Migkou, Magdalini
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    LEUKEMIA & LYMPHOMA, 2016, 57 (08) : 1776 - 1780
  • [42] IMPACT OF RENAL IMPAIRMENT ON THE EFFICACY AND SAFETY OF LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE (RD) IN CHINESE PATIENTS (PTS) WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): MM-021 TRIAL
    Zhou, D. B.
    Yu, L.
    Du, X.
    Jin, J.
    Cai, Z.
    Chen, F.
    Li, X.
    Wu, D.
    Meng, F.
    Ai, H.
    Zhang, J.
    Wortman-Vayn, H.
    Mei, J.
    Wang, J.
    Hou, J.
    HAEMATOLOGICA, 2014, 99 : 371 - 371
  • [43] LENALIDOMIDE PLUS HIGH-DOSE VERSUS LOW-DOSE DEXAMETHASONE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC REVIEW
    Kupas, K.
    Kaspar, I.
    Baecke, V.
    Weisel, K.
    HAEMATOLOGICA, 2017, 102 : 514 - 515
  • [44] A STATISTICAL COMPARISON OF THE EFFICACY AND SAFETY OF LOW-DOSE LENALIDOMIDE plus LOW- DOSE DEXAMETHASONE WITH FULL-DOSE LENALIDOMIDE plus DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Quach, H.
    Fernyhough, L.
    Henderson, R.
    Corbett, G.
    Honemann, D.
    Blacklock, H.
    Browett, P.
    Link, E.
    Cowan, L.
    Li, J.
    Swern, A.
    Hussein, M.
    Lynch, K.
    Dimopoulos, M.
    Prince, M.
    HAEMATOLOGICA, 2012, 97 : 350 - 351
  • [45] Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma
    Jung, Seung-Hyun
    Lee, Sung-Eun
    Lee, Minho
    Kim, So-Hee
    Yim, Seon-Hee
    Kim, Tae Woo
    Min, Chang-Ki
    Chung, Yeun-Jun
    HAEMATOLOGICA, 2017, 102 (11) : E456 - E459
  • [46] LENALIDOMIDE IN COMBINATION WITH LOW-DOSE DEXAMETHASONE IN RELAPSE/ REFRACTORY MULTIPLE MYELOMA: A RETROSPECTIVE STUDY
    Firatli-Tuglular, T.
    Noyan-Atalay, F.
    Eser, A.
    Toptas, T.
    Pepedil, F.
    Kaygusuz-Atagunduz, I.
    Adiguzel, C.
    HAEMATOLOGICA, 2013, 98 : 614 - 615
  • [47] IMPACT OF PRIOR THERAPY (TX) ON THE EFFICACY AND SAFETY OF LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE (RD) IN CHINESE PATIENTS (PTS) WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): MM-021 TRIAL
    Jin, J.
    Du, X.
    Cai, Z.
    Chen, F.
    Zhou, D. B.
    Yu, L.
    Li, X.
    Wu, D.
    Meng, F.
    Ai, H.
    Wang, J.
    Zhang, J.
    Wortman-Vayn, H.
    Mei, J.
    Hou, J.
    HAEMATOLOGICA, 2014, 99 : 375 - 375
  • [48] Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies
    Richardson, Paul G.
    Perrot, Aurore
    San-Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Huang, Jeffrey S. Y.
    Minarik, Jiri
    Cavo, Michele
    Prince, H. Miles
    Mace, Sandrine
    Malinge, Laure
    Dubin, Franck
    Morisse, Mony
    Anderson, Kenneth C.
    BLOOD, 2022, 140
  • [49] Isatuximab plus pomalidomide/low-dose dexamethasone versus pomalidomide/low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (ICARIA-MM): final overall survival analysis
    Richardson, Paul
    Perrot, Aurore
    San-Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Huang, Jeffrey Shang-Yi
    Minarik, Jiri
    Cavo, Michele
    Prince, H. Miles
    Malinge, Laure
    Dubin, Franck
    Morisse, Mony
    Anderson, Kenneth
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S32 - S32
  • [50] Phase Ib Multicenter Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM)
    Niesvizky, Ruben
    Wang, Luhua
    Orlowski, Robert Z.
    Bensinger, William
    Alsina, Melissa
    Gabrail, Nashat
    Gutierrez, Andres
    Kunkel, Lori
    Kauffman, Michael
    BLOOD, 2009, 114 (22) : 128 - 129
12345